Shana Claeys

Shana Claeys

Auto-generated profile, based on publicly available information

Shana Claeys

Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2018 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KEKristina B. Emdal
Kristina B. Emdal
APAnna-Kathrine Pedersen
Anna-Kathrine Pedersen
DBDorte B. Bekker-Jensen
Dorte B. Bekker-Jensen
ALAlicia Lundby
Alicia Lundby
SCShana Claeys
Shana Claeys
JOJesper V. Olsen
Jesper V. Olsen
An adaptor protein in the insulin signaling pathway enables the survival of aggressive neuroblastoma cells.

11 December 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
SCShana Claeys
Shana Claeys
GDGeertrui Denecker
Geertrui Denecker
KDKaat Durinck
Kaat Durinck
BDBieke Decaesteker
Bieke Decaesteker
LMLiselot M. Mus
Liselot M. Mus
FSFrank Speleman
Frank Speleman

14 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LMLiselot M. Mus
Liselot M. Mus
ILIrina Lambertz
Irina Lambertz
SCShana Claeys
Shana Claeys
CKCandy Kumps
Candy Kumps
WLWouter Van Loocke
Wouter Van Loocke
FSFrank Speleman
Frank Speleman
Neuroblastoma is an aggressive childhood cancer arising from sympatho-adrenergic neuronal progenitors. The low survival rates for high-risk disease point to an urgent need for novel targeted therapeutic approaches. Detailed molecular characterization of the neuroblastoma genomic landscape indicates that ALK-activating mutations are present in 10% of primary tumours. Together with other mutations causing RAS/MAPK pathway activation, ALK mutations are also enriched in relapsed cases and ALK activation was shown to accelerate MYCN-driven tumour formation through hitherto unknown ALK-driven target genes. To gain further insight into how ALK contributes to neuroblastoma aggressiveness, we searched for known oncogenes in our previously reported ALK-driven gene signature. We identified ETV5, a bona fide oncogene in prostate cancer, as robustly upregulated in neuroblastoma cells harbouring ALK mutations, and show high ETV5 levels downstream of the RAS/MAPK axis. Increased ETV5 expression significantly impacted migration, invasion and colony formation in vitro, and ETV5 knockdown reduced proliferation in a murine xenograft model. We also established a gene signature associated with ETV5 knockdown that correlates with poor patient survival. Taken together, our data highlight ETV5 as an intrinsic component of oncogenic ALK-driven signalling through the MAPK axis and propose that ETV5 upregulation in neuroblastoma may contribute to tumour aggressiveness.